Latest Pharma Insights
Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Kangtai Drops Plan for China Vaccine JV With AstraZeneca
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Zimmer Biomet Pushes Two-Year US Sales Restructuring, May See Near Term Headwinds
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet Expects Paragon 28 To Power Double Digit Rise In 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
Korea Q4 Roundup: Major Firms’ Results Largely Favorable
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
US FDA’s Worldwide GMP Warnings Stack Up With Problems Found At Topical OTC Drug Firms
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
Estée Lauder Sues Walmart Alleging Sale of Counterfeit Beauty Products
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Scrip - February 12, 2026
Kangtai Drops Plan for China Vaccine JV With AstraZeneca
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip - February 12, 2026
Korea Q4 Roundup: Major Firms’ Results Largely Favorable
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
Aside from logging generally solid earnings, South Korean pharma firms Yuhan, Hanmi and SK Biopharmaceuticals disclosed updated R&D strategies involving obesity treatments and new modalities.
Scrip - February 12, 2026
Zimmer Biomet Pushes Two-Year US Sales Restructuring, May See Near Term Headwinds
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet has strengthened its product pipeline and addressed prior portfolio gaps. However, successful execution of the sales force transformation now appears to be the critical factor in sustaining mid-single-digit organic growth and delivering positive operating leverage.
Medtech Insight - February 12, 2026
Zimmer Biomet Expects Paragon 28 To Power Double Digit Rise In 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
In the fourth quarter, Zimmer Biomet's US knee revenue grew 6%, short of Stryker's 8% but ahead of Johnson & Johnson's 5%. Zimmer Biomet's US hip revenue growth was particularly strong at 8%, outpacing Stryker's 6% and J&J's 4%.
Medtech Insight - February 12, 2026
US FDA’s Worldwide GMP Warnings Stack Up With Problems Found At Topical OTC Drug Firms
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
“Your firm’s quality systems are inadequate” or “these products are unapproved new drugs” each firm warned with reference to FDA’s regulation for GMPs for pharmaceuticals, supplements or cosmetics. Warnings included 10 to firms about GMP violations topical drugs production.
HBW Insight - February 12, 2026
Estée Lauder Sues Walmart Alleging Sale of Counterfeit Beauty Products
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
The Estee Lauder Companies alleges retail giant Walmart has been ‘knowingly’ selling counterfeit versions of products from six of its brands. It filed a lawsuit against the firm Feb. 9.
HBW Insight - February 12, 2026
CVS To Prefer Denosumab Biosimilars, Drop Prolia From Key US Formularies
Samsung Bioepis’ Ospomyv and Celltrion’s Stoboclo will be preferred on major US commercial formularies from April 2026, as CVS Caremark drops Prolia and another higher-cost brand, Forteo (teriparatide), to drive savings.
Generics Bulletin - February 11, 2026
Samsung Bioepis’ Ospomyv and Celltrion’s Stoboclo will be preferred on major US commercial formularies from April 2026, as CVS Caremark drops Prolia and another higher-cost brand, Forteo (teriparatide), to drive savings.
Generics Bulletin - February 11, 2026
Formycon Strikes A Keytruda Biosimilar Deal With Lotus For APAC Markets
Formycon bagged a third commercialization opportunity for its pembrolizumab candidate FYB206, with Lotus Pharmaceutical taking over rights for the APAC region.
Generics Bulletin - February 11, 2026
Formycon bagged a third commercialization opportunity for its pembrolizumab candidate FYB206, with Lotus Pharmaceutical taking over rights for the APAC region.
Generics Bulletin - February 11, 2026
Intas And Kashiv Ally On Complex Peptide
Kashiv Biosciences and Intas Pharmaceuticals have announced a licensing and supply collaboration on an undisclosed complex peptide for the European, UK and Indian markets.
Generics Bulletin - February 11, 2026
Kashiv Biosciences and Intas Pharmaceuticals have announced a licensing and supply collaboration on an undisclosed complex peptide for the European, UK and Indian markets.
Generics Bulletin - February 11, 2026
Celltrion Outlines Plan To Quadruple Biosimilar Portfolio By 2038
The Korean player plans to expand its biosimilar portfolio to more than 40 products by 2038, while advancing late-stage candidates including a streamlined Phase III trial of its secukinumab biosimilar.
Generics Bulletin - February 11, 2026
The Korean player plans to expand its biosimilar portfolio to more than 40 products by 2038, while advancing late-stage candidates including a streamlined Phase III trial of its secukinumab biosimilar.
Generics Bulletin - February 11, 2026
Immunis Bets Longevity Medicine Needs a Business Model, Not Just Biology
Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.
In Vivo - February 11, 2026
Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.
In Vivo - February 11, 2026